320 related articles for article (PubMed ID: 15115397)
1. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.
Das K; Clark AD; Lewi PJ; Heeres J; De Jonge MR; Koymans LM; Vinkers HM; Daeyaert F; Ludovici DW; Kukla MJ; De Corte B; Kavash RW; Ho CY; Ye H; Lichtenstein MA; Andries K; Pauwels R; De Béthune MP; Boyer PL; Clark P; Hughes SH; Janssen PA; Arnold E
J Med Chem; 2004 May; 47(10):2550-60. PubMed ID: 15115397
[TBL] [Abstract][Full Text] [Related]
2. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Das K; Lewi PJ; Hughes SH; Arnold E
Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.
Lansdon EB; Brendza KM; Hung M; Wang R; Mukund S; Jin D; Birkus G; Kutty N; Liu X
J Med Chem; 2010 May; 53(10):4295-9. PubMed ID: 20438081
[TBL] [Abstract][Full Text] [Related]
4. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Tian XT; Xie L
Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
[TBL] [Abstract][Full Text] [Related]
5. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
7. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
8. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.
Das K; Bauman JD; Clark AD; Frenkel YV; Lewi PJ; Shatkin AJ; Hughes SH; Arnold E
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1466-71. PubMed ID: 18230722
[TBL] [Abstract][Full Text] [Related]
9. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.
Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Chan JH; Kleim JP; Stammers DK
J Med Chem; 2007 May; 50(10):2301-9. PubMed ID: 17441703
[TBL] [Abstract][Full Text] [Related]
10. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
11. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
12. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
13. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
Ribone SR; Quevedo MA; Madrid M; Briñón MC
J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
[TBL] [Abstract][Full Text] [Related]
14. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
15. [Chemical characteristics, mechanism of action and antiviral activity of etravirine].
García FG; Estévez MA; Suay VG
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():2-5. PubMed ID: 20116621
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs.
Chen X; Zhan P; Li D; De Clercq E; Liu X
Curr Med Chem; 2011; 18(3):359-76. PubMed ID: 21143120
[TBL] [Abstract][Full Text] [Related]
18. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
19. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
[TBL] [Abstract][Full Text] [Related]
20. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]